Raphas Co., Ltd.
Financials
Valuation Metrics
Raphas Co., Ltd.'s Market Cap is ₩620B. At end of 2025 it was ₩1169B. Ranked #1560 of 2,410 in KR market (top 65%), #911 of 1,631 on KOSDAQ (top 56%), #32 of 56 in Household & Personal Products (top 57%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 62.01B KRW | KR#1,560/2,410 Sec#32/56 |
| Revenue | 30.16B KRW | KR#2,026/2,410 Sec#46/56 |
| Net Income | -6.11B KRW | KR—/2,410 Sec—/56 |
| Total Assets | 67.97B KRW | KR#2,034/2,410 Sec#44/56 |
| Net Assets | 27.54B KRW | KR#2,199/2,410 Sec#50/56 |
| Employees | 100 | KR#1,632/2,410 Sec#35/56 |
| Value | ||
| P/B | 2.25x | KR#2,035/2,410 Sec#47/56 |
| P/S | 2.06x | KR#1,870/2,410 Sec#46/56 |
| FCF Yield | 1.34% | KR#1,114/2,410 Sec#32/56 |
| Profitability | ||
| ROE | -22.19% | KR#2,106/2,410 Sec#49/56 |
| ROA | -8.99% | KR#2,073/2,410 Sec#50/56 |
| Op. Margin | -12.98% | KR#2,034/2,410 Sec#49/56 |
| Revenue Growth | 4.55% | KR#1,217/2,410 Sec#31/56 |
| Earnings Growth | -2953.76% | KR#1,341/2,410 Sec#35/56 |
| Financial Health | ||
| Debt Ratio | 146.81% | KR#1,880/2,410 Sec#48/56 |
| Total Debt | 38.04B KRW | KR#1,120/2,410 Sec#22/56 |
| FCF | 828.0M KRW | KR#1,157/2,410 Sec#30/56 |
| Cash | 12.34B KRW | KR#1,564/2,410 Sec#27/56 |
| Current Ratio | 0.77x | KR#1,966/2,410 Sec#43/56 |
| Performance | ||
| 1Y Return | -44.89% | KR#1,919/2,410 Sec#43/56 |
| 1M Return | -9.03% | KR#923/2,410 Sec#23/56 |
| From 52W High | -58.31% | KR#1,573/2,410 Sec#40/56 |
| 1Y MDD | -55.76% | KR#1,207/2,410 Sec#36/56 |
| Trading | ||
| Volume | 3,408 shares | KR#1,958/2,410 Sec#46/56 |
| Trading Value | 23.4M KRW | KR#1,744/2,410 Sec#38/56 |
| Foreign Own. | 0.00% | KR—/2,410 Sec—/56 |
| Per Share | ||
| EPS | -685 KRW | KR—/2,410 Sec—/56 |
| BPS | 3,086 KRW | KR#1,854/2,410 Sec#41/56 |
Company Info
Raphas, established in 2006 and headquartered in Gangseo-gu, Seoul, was listed on KOSDAQ as a technology growth company in 2019. It specializes in the research, development, manufacturing, and sales of soluble microneedle patches, a transdermal drug delivery technology. While current sales are primarily in cosmetic fields like beauty patches, the company is expanding its business into pharmaceuticals, vaccine patches, and medical devices. Its unique DEN technology allows for microneedle production in about 5 minutes using only room-temperature air circulation, without UV light, and offers flexible control over length and pattern without molds.